Abstract
The low incidence of gastric cancer in the US presents various quality challenges. For most US practitioners, individual experience is inadequate. Accrual to clinical trials testing new treatments can be daunting. However, through the use of nationally available clinical trials sponsored by many trial groups working in concert, and the use of national registries for treatment and outcome surveillance, a path to increased gastric cancer survival has been charted. Moreover, systems for continuous quality improvement at the institutional level are in place. Quality assurance is an increasing concern of both private and governmental groups. In this article, we summarize recent national US clinical trial findings concerning gastric cancer treatment, highlight national assessment systems for cancer outcomes, and describe what these systems tell us about the current status of gastric cancer care in the US, highlighting challenges and areas for potential improvement.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 605-615 |
| Number of pages | 11 |
| Journal | European Journal of Surgical Oncology |
| Volume | 31 |
| Issue number | 6 SPEC. ISS. |
| DOIs | |
| State | Published - Aug 2005 |
Fingerprint
Keywords
- Chemo-radiation
- Gastric cancer
- Maruyama Index
- Outcomes
- Quality
- Surgery
- Surveillance
ASJC Scopus subject areas
- Oncology
- Surgery
Cite this
Changing gastric cancer treatment in the United States and the pursuit of quality. / Hundahl, Scott A; Wanebo, H. J.
In: European Journal of Surgical Oncology, Vol. 31, No. 6 SPEC. ISS., 08.2005, p. 605-615.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Changing gastric cancer treatment in the United States and the pursuit of quality
AU - Hundahl, Scott A
AU - Wanebo, H. J.
PY - 2005/8
Y1 - 2005/8
N2 - The low incidence of gastric cancer in the US presents various quality challenges. For most US practitioners, individual experience is inadequate. Accrual to clinical trials testing new treatments can be daunting. However, through the use of nationally available clinical trials sponsored by many trial groups working in concert, and the use of national registries for treatment and outcome surveillance, a path to increased gastric cancer survival has been charted. Moreover, systems for continuous quality improvement at the institutional level are in place. Quality assurance is an increasing concern of both private and governmental groups. In this article, we summarize recent national US clinical trial findings concerning gastric cancer treatment, highlight national assessment systems for cancer outcomes, and describe what these systems tell us about the current status of gastric cancer care in the US, highlighting challenges and areas for potential improvement.
AB - The low incidence of gastric cancer in the US presents various quality challenges. For most US practitioners, individual experience is inadequate. Accrual to clinical trials testing new treatments can be daunting. However, through the use of nationally available clinical trials sponsored by many trial groups working in concert, and the use of national registries for treatment and outcome surveillance, a path to increased gastric cancer survival has been charted. Moreover, systems for continuous quality improvement at the institutional level are in place. Quality assurance is an increasing concern of both private and governmental groups. In this article, we summarize recent national US clinical trial findings concerning gastric cancer treatment, highlight national assessment systems for cancer outcomes, and describe what these systems tell us about the current status of gastric cancer care in the US, highlighting challenges and areas for potential improvement.
KW - Chemo-radiation
KW - Gastric cancer
KW - Maruyama Index
KW - Outcomes
KW - Quality
KW - Surgery
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=22144431580&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22144431580&partnerID=8YFLogxK
U2 - 10.1016/j.ejso.2005.02.011
DO - 10.1016/j.ejso.2005.02.011
M3 - Article
C2 - 16023944
AN - SCOPUS:22144431580
VL - 31
SP - 605
EP - 615
JO - Clinical Oncology
JF - Clinical Oncology
SN - 0748-7983
IS - 6 SPEC. ISS.
ER -